Wells Fargo & Company Uro Gen Pharma Ltd. Transaction History

Wells Fargo & Company

$429 Billion
Q1 2025

A detailed history of Wells Fargo & Company transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Wells Fargo & Company holds 216,478 shares of URGN stock, worth $4.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

216,478

Previous 221,540 2.28%

Holding current value

$4.16 Million

Previous $2.36 Million 1.48%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$9.27 - $12.13 $46,924 - $61,402	-5,062 Reduced 2.28%	216,478 $2.39 Million
Q4 2024 Feb 12, 2025	BUY	$10.52 - $13.11 $61,026 - $76,051	5,801 Added 2.69%	221,540 $2.36 Million
Q3 2024 Nov 13, 2024	SELL	$12.7 - $17.92 $1,295 - $1,827	-102 Reduced 0.05%	215,739 $2.74 Million
Q2 2024 Aug 13, 2024	BUY	$12.72 - $19.2 $45,295 - $68,371	3,561 Added 1.68%	215,841 $3.62 Million
Q1 2024 May 10, 2024	SELL	$13.81 - $19.33 $93,921 - $131,463	-6,801 Reduced 3.1%	212,280 $3.18 Million
Q4 2023 Feb 09, 2024	BUY	$10.87 - $15.93 $27,696 - $40,589	2,548 Added 1.18%	219,081 $3.29 Million
Q3 2023 Nov 13, 2023	SELL	$8.84 - $22.64 $1.87 Million - $4.78 Million	-211,004 Reduced 49.35%	216,533 $3.03 Million
Q2 2023 Aug 15, 2023	BUY	$8.75 - $14.29 $34,973 - $57,117	3,997 Added 0.94%	427,537 $4.43 Million
Q1 2023 May 12, 2023	BUY	$7.99 - $11.02 $274,576 - $378,702	34,365 Added 8.83%	423,540 $3.91 Million
Q4 2022 Feb 13, 2023	SELL	$7.55 - $11.96 $29,920 - $47,397	-3,963 Reduced 1.01%	389,175 $3.45 Million
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.41 $17,844 - $23,289	2,475 Added 0.63%	393,138 $3.27 Million
Q2 2022 Aug 12, 2022	BUY	$5.12 - $8.74 $699,755 - $1.19 Million	136,671 Added 53.81%	390,663 $3.2 Million
Q1 2022 May 16, 2022	BUY	$5.92 - $9.73 $491,946 - $808,553	83,099 Added 48.63%	253,992 $2.21 Million
Q4 2021 Feb 14, 2022	BUY	$9.03 - $19.13 $329,197 - $697,403	36,456 Added 27.12%	170,893 $1.63 Million
Q3 2021 Nov 15, 2021	BUY	$14.31 - $18.39 $1.64 Million - $2.11 Million	114,521 Added 575.02%	134,437 $2.26 Million
Q2 2021 Aug 16, 2021	BUY	$15.2 - $20.94 $238,077 - $327,983	15,663 Added 368.28%	19,916 $304,000
Q1 2021 May 13, 2021	SELL	$17.99 - $26.96 $535,526 - $802,545	-29,768 Reduced 87.5%	4,253 $83,000
Q4 2020 Feb 09, 2021	BUY	$17.54 - $25.43 $99,153 - $143,755	5,653 Added 19.93%	34,021 $613,000
Q3 2020 Nov 05, 2020	SELL	$18.81 - $26.42 $84,870 - $119,207	-4,512 Reduced 13.72%	28,368 $547,000
Q2 2020 Aug 13, 2020	BUY	$16.5 - $29.7 $340,989 - $613,780	20,666 Added 169.2%	32,880 $859,000
Q1 2020 May 14, 2020	BUY	$13.68 - $34.6 $167,087 - $422,604	12,214 New	12,214 $218,000

Others Institutions Holding URGN

# of Institutions

148

Shares Held

44M

Call Options Held

146K

Put Options Held

42.1K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $437M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Uro Gen Pharma Ltd. Transaction History